Azora Therapeutics
22 hedge funds and large institutions have $2.81M invested in Azora Therapeutics in 2026 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 2 closing their positions.
2,233% more capital inflows, than outflows
Capital inflows: $2.58M | Capital outflows: $111K
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
250% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 2
29% more funds holding
Funds holding: 17 → 22 (+5)
20.3% more ownership
Funds ownership: 6.37% → 26.67% (+20%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KVP Capital Advisors
San Francisco,
California
|
+$904K |
| 2 |
Diadema Partners
Morristown,
New Jersey
|
+$782K |
| 3 |
Acuta Capital Partners
Redwood City,
California
|
+$559K |
| 4 |
XTX Topco
George Town,
Cayman Islands
|
+$115K |
| 5 |
Jane Street
New York
|
+$93.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$75.1K |
| 2 |
StoneX Group
New York
|
-$35.7K |
| 3 |
SBI Securities
Tokyo,
Japan
|
-$9 |
| 4 |
Harbour Investments
Madison,
Wisconsin
|
-$8 |
AZR Hedge Fund Activity: Q3 2026 in Review
22 of the 8,227 institutional investors tracked by Wall St. Rank reported a position in Azora Therapeutics (AZR) for Q3 2026, worth a combined $2.81M — up 740% from $335K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new AZR positions and 2 closed out — a net gain of 5 holders — while 7 added to existing stakes and 2 trimmed.
The largest buyer was KVP Capital Advisors, opening a new position worth an estimated $904K. The largest seller was UBS Group, cutting an estimated $75.1K.
- 22 institutional investors held Azora Therapeutics (AZR) as of Q3 2026, up from 17 in Q2 2026.
- Funds reported $2.81M of Azora Therapeutics stock for Q3 2026, up 740% quarter-over-quarter.
- 7 funds opened new Azora Therapeutics positions in Q3 2026 and 2 closed out, a net change of +5 holders.
- The largest Azora Therapeutics buyer in Q3 2026 was KVP Capital Advisors, an estimated $904K added.
- The largest Azora Therapeutics seller in Q3 2026 was UBS Group, an estimated $75.1K sold.
Based on aggregated 13F filings for Q3 2026.